Zafirlukast, like other LTRAs, operates by inhibiting the immune program. As a result of its motion on inflammatory cells during the lungs, zafirlukast minimizes the manufacture of inflammatory mediators which can be implicated from the pathogenesis of bronchial asthma. You can find some analysis